Skip to content

Polygenic Scores for Cardiometabolic Diseases Correlate Strongly Across Siblings

Key findings

  • Researchers at Massachusetts General Hospital previously calculated polygenic scores for coronary artery disease (CAD), atrial fibrillation, diabetes and severe obesity (BMI ≥40 kg/m2)
  • In this study, using data on relatives from the UK Biobank, correlations of polygenic scores for CAD were r=1.0 (perfect) between 179 pairs of monozygotic twins and r=0.51 between 22,644 sibling pairs; similar results were observed for the other diseases
  • When a high polygenic score was defined as the top 20% of the distribution—corresponding to a more than doubling of risk for each of the four diseases—about 45% of siblings similarly met that threshold
  • When an individual proves to have a high polygenic score for a cardiometabolic disease, cascade testing to identify additional family members with a high score may be warranted

Polygenic scores integrate information from many common DNA variants into a single measure and quantify an individual's inherited risk of a given disease. Now Amit V. Khera, MD, MSc, cardiologist, a researcher in the Center for Genomic Medicine, and medical director of the Preventive Genomics Clinic at Massachusetts General Hospital, and colleagues have characterized what a high polygenic score means for the individual's family members. Their findings are published as a research letter in Circulation: Genomic and Precision Medicine.

Correlations Between Relatives

The researchers previously calculated polygenic scores for coronary artery disease (CAD), atrial fibrillation (AF), diabetes and severe obesity (BMI ≥40 kg/m2). Using data on relatives from the UK Biobank, they found that for CAD, correlations of polygenic scores were:

  • r=1.0 (perfect) between 179 pairs of monozygotic twins
  • r=0.51 between 22,644 sibling pairs
  • r=0.25 between 11,123 pairs of second-degree relatives

Nearly identical results were observed across the other diseases.

Predictive Value of a High Score

There is no standard for what a "high" polygenic score is, so the team explored multiple thresholds, including the top 1% and top 20% of the disease-specific distributions (the latter represents more than doubling of the risk):

  • CAD—For individuals with a polygenic score in the top 1%, 21% of siblings' polygenic scores met the same threshold; for those in the top 20%, 44% of siblings' scores met the same threshold
  • AF—15% and 46%, respectively
  • Diabetes—12% and 44%, respectively
  • Severe obesity—13% and 44%, respectively

The positive predictive value of a high polygenic score was largely independent of family history.

Disease Discordance

Disease discordance between sibling pairs was observed for:

  • CAD—1,844 pairs
  • AF—1,430 pairs
  • Diabetes—2,376 pairs
  • Severe obesity—749 pairs

The higher polygenic score was observed in the affected sibling in 1,071 (58%) of the pairs with discordant CAD status, significantly higher than the 50% that would be observed by chance (P<0.001). The pattern was similar across the three other diseases: 60% of pairs for AF, 60% for diabetes, and 67% for severe obesity.

Implications for Genetic Counseling

When an individual proves to have a high polygenic score for cardiometabolic disease, cascade testing to identify additional family members with a high score may be warranted. Individuals with high inherited risk may benefit from targeted screening for the disease and preventive interventions.

Learn more about the Center for Genomic Medicine

Refer a patient to the Corrigan Minehan Heart Center

Related

In the most detailed study to date, Mayara Bearse, MD, and James R. Stone, MD, PhD, of the Department of Pathology, and colleagues, cardiac infection by SARS-CoV-2 was evident in 73% of autopsies of patients who died of COVID-19 and was linked to differences in clinical features and treatment.

Related

Variants in chromosome Xq23 are linked to reduced total cholesterol, LDL cholesterol and triglycerides, and reduced risk of coronary heart disease and type 2 diabetes, according to whole-genome data analyzed by Pradeep Natarajan, MD, MMSc, and an international team of colleagues.